<DOC>
	<DOCNO>NCT00669487</DOCNO>
	<brief_summary>This protocol aim determine risk/benefits policy compare head-to-head regimen GPO-VIR Z TDF/FTC/NVP 18 month ARV-naïve patient 6-month lead GPO-VIR S follow 12 month GPO-VIR Z . The primary outcome assess anemia , neuropathy , lipoatrophy renal function .</brief_summary>
	<brief_title>A 72-week Randomized Clinical Trial Comparing Safety Efficacy Three Initial Antiretroviral Regimens -GPO-VIR S ( d4T/3TC/NVP ) 24 Weeks Followed GPO-VIR Z ( AZT/3TC/NVP ) vs GPO-VIR Z v TDF/FTC/NVP</brief_title>
	<detailed_description>GPO-VIR Z new combination antiretroviral ( ARV ) medication substitute zidovudine ( AZT ) stavudine ( d4T ) original formulation GPO-VIR S. This new combination decrease rate lipoatrophy neuropathy side-effects strongly link use d4T . However , risk initiate therapy AZT- contain regimen may cause unacceptable rate anemia . Many Thai physician adopt practice use 6 month stavudine-containing GPO-VIR S lead introduce AZT-containing GPO-VIR Z effort balance risk benefit two medication . There definitive data , however , attest benefit approach .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<criteria>1 . Documented HIV1 infection 2 . Age ≥ 18 year old . 3 . Subjects must naïve ARV . Individuals past exposure ARV associate pregnancy allow enroll long exposure least 3 month prior entry . 4 . CD4 &lt; 350 cells/mm3 5 . Subject understands study able sign inform consent 1 . Evidence symptomatic persistent symptom tingle numbness low extremity bilateral low extremity neuropathy exam entry . Abnormal exam include 1 ) Diminished ( compare knee ) absent ankle reflex OR 2 ) Diminution either vibration sensation leg ( define perception vibration &lt; 10 second great toe tune fork initially strike hard enough audible ) OR 3 ) Diminution pin temperature sensation low extremity OR 4 ) Contact allodynia foot . 2 . Laboratory value 1 ) Absolute neutrophil count ( ANC ) &lt; 750/mm3 2 ) Hemoglobin &lt; 8.0 g/dL 3 ) ALT ( SGPT ) &gt; 5 x ULN 4 ) Creatinine &gt; 2 X ULN &lt; creatinine clearance &lt; 30 cc per min CockroftGault formula 3 . Active AIDSdefining opportunistic infection ( OI ) within 30 day prior entry . Subjects must acute treatment OI least 14 day prior entry . Subjects maintenance prophylactic therapy AIDSrelated OIs eligible . 4 . Any immunomodulator , HIV vaccine investigational therapy within 30 day study entry 5 . Pregnancy breastfeeding ; intent become pregnant course study . 6 . Presence active malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>HIV/AIDS patient</keyword>
</DOC>